A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies
AD Elias(Harvard University), Robin Joyce(Beth Israel Deaconess Medical Center), Paul G. Richardson(Harvard University), David Avigan(Beth Israel Deaconess Medical Center), Mary McCauley(Harvard University), Joseph G. Ibrahim(University of North Carolina at Chapel Hill), Catherine Wheeler(Harvard University), D Warren(Beth Israel Deaconess Medical Center), David F. McDermott(Beth Israel Deaconess Medical Center), J Levine
Cited by 5
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k